Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets the T790M mutation of EGFR. In 2016, AstraZeneca conducted a compassionate use program for osimertinib in Japan. Methods: Eighteen consecutive patients with histologically proven non-small-cell lung cancer (NSCLC) and harboring the T790M EGFR mutation participated in the compassionate use program between 1 April and 25 May 2016, at the National Cancer Center Hospital. We examined the efficacy and safety of osimertinib in a compassionate use program. Results: All patients had been previously treated with both cytotoxic chemotherapy and EGFR TKIs. Overall response rate was 62.5% (95% confidence interval (CI): 35.9-89.1%). Among the six patients pretreated with a third-generation EGFR TKI, two (33%) responded to osimertinib. On administration with osimertinib, median progression-free and overall survival rates at six months were 66.7% (95% CI: 44.9-88.5) and 88.9% (95% CI: 74.4-100), respectively. Although the toxicity of osimertinib was mild in most patients, three patients had severe adverse events: two developed interstitial lung disease (ILD) and one developed Grade 3 hepatotoxicity. Among these, two (33%) of the six patients who received osimertinib following nivolumab treatment developed severe adverse events, with one each developing Grade 3 hepatotoxicity and Grade 3 ILD. Only one patient visited our hospital seeking to participate in the compassionate program from another hospital. Conclusion: Osimertinib demonstrated efficacy even in patients with heavily pretreated NSCLC harboring the T790M mutation. Some patients pretreated with another third-generation EGFR TKI also responded to osimertinib.
Introduction
The discovery of driver mutations in the epidermal growth factor receptor (EGFR) gene has led to a dramatic paradigm shift in therapeutic strategies for advanced non-small-cell lung cancer (NSCLC). First-and second-generation tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, are standard therapies for patients with advanced NSCLC harboring mutations in the EGFR gene, including exon 19 deletions and L858R mutation in exon 21 (1) (2) (3) (4) (5) (6) . However, acquired resistance to TKIs frequently develops within 1 or 2 years after initiating therapy. The most common mechanism of acquired resistance, accounting for 60% of cases, is the occurrence of the secondary mutation T790M, in which a gatekeeper amino acid is replaced (7) (8) (9) (10) . To overcome resistance to first-and second-generation EGFR-TKIs, we have developed a new generation of drugs that suppress the kinase activity of EGFR harboring the T790M mutation (11) (12) (13) .
Osimertinib is a third-generation EGFR TKI that is selective for EGFR TKI-sensitizing mutations and the T790M resistance mutation. Two clinical trials, AURA extension and AURA 2, have demonstrated the efficacy of osimertinib in patients whose cancers had progressed from or after treatment with an EGFR TKI and whose tumors tested positive for the EGFR T790M mutation (14, 15) . On the basis on these results, the Japanese Ministry of Health, Labour and Welfare approved osimertinib on 28 March 2016, which follows the United States Food and Drug Administration Accelerated Approval in November 2015 and the European Commission conditional marketing authorization in February 2016. Moreover, the Japanese National Health Insurance system listed the reimbursement price of osimertinib on 26 May 2016. A recent Phase III trial further revealed the effectiveness of osimertinib, wherein median progression-free survival (PFS) in patients with T790M-positive advanced NSCLC in whom the disease had progressed during first-line EGFR-TKI therapy was significantly longer with osimertinib than with platinum therapy plus pemetrexed (16) .
Compassionate use is a treatment option that allows the access unapproved drugs exceptiomnally to treat patients with lifethreatening or serious disabling disease. The Japanese Ministry of Health, Labour and Welfare established the extended investigational trial system (Japanese compassionate use program, cohort type) from January 2016, On the other hand, some pharmaceutical companies have been the major proponents in their own compassionate use programs, such as on gefitinib for NSCLC, crizotinib for ALK-positive NSCLC, and nivolumab for malignant melanoma. AstraZeneca also conducted a compassionate use program for osimertinib under special or specified medical care coverage in Japan between 1 April and 25 May 2016. Here, we outline this compassionate use program in Japan and report the efficacy and safety of osimertinib under compassionate use.
Patients and methods

Subjects
Eighteen patients with histologically proven NSCLC harboring the T790M EGFR mutation were prospectively registered in a compassionate use program at the National Cancer Centre Hospital (NCCH), all of whom were treated with osimertinib. We retrospectively reviewed medical records of these patients, including patient characteristics, histology, type of EGFR mutation, the rebiopsy procedure to confirm T790M mutation, timing and purpose of referral to the NCCH and treatment history. The Institutional Review Board of the NCCH approved this observational study.
Study treatment and assessment
Patients received the standard osimertinib dose of 80 mg once a day until disease progression, clinical deterioration or unacceptable toxicity was confirmed. We assessed EGFR mutation status using high sensitivity mutation assays, including the cycleave PCR method, amplification refractory mutation system (ARMS) method and BML PCR invader Assay.
Adverse events were graded according to the Common Terminology Criteria for Adverse Events version 4.03. Objective tumor response was evaluated every 3 or 4 months according to the Response Evaluation Criteria I Solid Tumors (RECIST version 1.1) (17) . PFS and overall survival (OS) were measured from the initiation date of osimertinib administration until disease progression, death, or the final day of the follow-up period, whichever occurred first. Median survival was calculated using the Kaplan-Meier method. We performed the final analysis on adverse events and efficacy on 8 December 2016. All statistical analyses were carried out using SPSS statistics version 23.0 (SPSS, Chicago, IL, USA).
Results
Patient characteristics
On 27 March 2016, AstraZeneca conducted a compassionate use program for osimertinib in multiple institutions in Japan between 1 April and 25 May. A total of 18 patients were administered osimertinib under this program at the NCCH (Table 1 , Fig. 1 ). Patients (female, 10; male, 8) had a median age of 67 years (range: 42-80 years) and all had been diagnosed with lung adenocarcinoma with the exon 19 deletion (n = 13) or exon 21 L858R mutation (n = 5).
Rebiopsy to confirm a T790M mutation from the primary lung cancer (n = 8), pleural effusion (n = 5), lung metastasis (n = 2), mediastinal lymph node (n = 1), pleural dissemination (n = 1), and liver metastasis (n = 1) was performed at NCCH (n = 16) or a former hospital (n = 2) ( Table 2 ). The rebiopsy procedure consisted of trans-bronchial lung biopsy (n = 8), pleural effusion using the cellblock technique (n = 5), CT-guided needle biopsy (n = 3), or endobronchial ultrasonography (n = 2). All 18 patients had been previously treated with both cytotoxic chemotherapy and EGFR TKI, with five (28%) also having received surgical resection, and five (28%) palliative radiotherapy (Supplemental Table 1 ). Median number of regimens previously treated with all chemotherapy, cytotoxic agents, and EGFR-TKI were 4 (range: 2-10), 1 (0-10), and 2 (1-4), respectively. Eight (44%) had previously been treated with immune checkpoint inhibitors including nivolumab (n = 6) and six (33%) with third-generation EGFR TKIs other than osimertinib as investigational drugs at the NCCH. Reasons for the discontinuation of third-generation EGFR TKIs were progressive disease (PD) (n = 5) and adverse events (n = 1).
Treatment efficacy and toxicity
In all patients, median PFS and OS rates at six months were 66.7% (95% confidence interval (CI): 44.9-88.5) and 88.9% (95% CI: 74.4-100), respectively (Supplemental Figure 1) . Of the 16 patients with measurable lesion by RECIST v1.1, 10 had partial response (PR), three had stable disease, and three had progressive disease as their best response. The overall response rate by RECIST was 62.5% (95% CI: 35.9-89.1%) (Fig. 2) . Of the six patients previously treated with third-generation EGFR TKIs, two patients (33%) responded to osimertinib.
Although the toxicity of osimertinib was mild in most patients, two patients developed interstitial lung disease (ILD) and one developed grade 3 hepatotoxicity (Table 3) . Among these, two (33%) of the six patients who received osimertinib following nivolumab treatment developed severe adverse events: one developed Grade 3 hepatotoxicity and another developed Grade 3 ILD (55 and 74 days after the last dose of nivolumab, respectively).
Compassionate use program in Japan
Our patients were referred to the NCCH at the time of initial diagnosis of chemotherapy-naïve, advanced or recurrent NSCLC (n = 8), or after receiving chemotherapy in a previous hospital with known (n = 2) or unknown T790M mutation (n = 8) (Fig. 1) . The reasons underlying the referral of the 10 patients who had received chemotherapy in a former hospital were participation in a clinical trial of any third-generation EGFR-TKI (n = 5), participation in the compassionate program for osimertinib (n = 1), and receipt of unspecified treatment (n = 4).
Although AstraZeneca announced this compassionate use program for osimertinib through multiple media sources on 28 March 2016, only one patient visited our hospital seeking to participate in the compassionate program from another hospital.
Discussion
Under the compassionate use program, osimertinib demonstrated sufficient efficacy even in patients with heavily pretreated NSCLC harboring the T790M EGFR mutation. Recently, osimertinib showed a significant improvement in PFS compared with platinum-based doublet chemotherapy in patients with EGFR T790M-positive, advanced NSCLC who had progressed after EGFR-TKI therapy (AURA3), and osimertinib is the standard therapy for such patients (16) . In our PPE, palmar-planter erythrodysesthesia; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase; HZV, herpes zoster virus.
Three patients developed clinically significant adverse events: Grade 2 interstitial lung disease (n = 1), Grade 3 interstitial lung disease (n = 1), and Grade 3 AST/ALT increase (n = 1).
patients, PFS and OS were comparable to those from clinical trials for osimertinib with a short follow-up period (14) (15) (16) . In particular, two of our six patients who had previously received another thirdgeneration EGFR TKI responded to osimertinib.
In preclinical models, the IC 50 of osimertinib in normal tissue with wild type EGFR was much higher than that in cancer tissue with EGFR mutations, including exon 19 deletions and L858R and T790M mutations. Therefore, based on clinical trial results, we had expected the toxicity of osimertinib to be mild in most patients. However, among the six patients who received osimertinib following nivolumab, one developed Grade 3 hepatotoxicity and another developed grade 3 ILD (55 and 74 days after the last dose of nivolumab, respectively). Some targeted agents can affect immunological status in tumors and tumor microenvironments (18) . For example, previous reports indicate that patients receiving osimertinib in combination with an anti-PD-L1 antibody had a higher incidence of ILD (19, 20) . Besides, all six patients harboring EGFR mutation in our study had insufficient efficacy on nivolumab without response as well as in clinical trials (21, 22) . We therefore propose that nivolumab treatment should be avoided in patients with an EGFR mutation who will receive osimertinib as a post-treatment, or alternatively not for at least several months after their last dose of nivolumab.
The overall number of patients referred to our hospital for participation in the compassionate program was very low. There may be several reasons for this. First, many patients with T790M-positive advanced NSCLC may have participated in other clinical trials for third-generation EGFR TKIs. Second, nivolumab was approved for NSCLC in Japan at the end of December 2015, ahead of osimertinib. Third, the length of the compassionate use program was only about eight weeks, which was a short period to confirm T790M mutation by rebiopsy; however, it was sufficient time to continue EGFR TKI beyond PD. Actually, we underwent rebiopsy in 18 patients to confirm a T790M mutation after March 2016. Among twelve (67%) patients with T790M-positive NSCLC, eight patients received osimertinib as compassionate use in this study and the other four received osimertinib as clinical practice after finishing compassionate use program. Five were diagnosed with T790M-negative NSCLC and the remaining one was insufficient specimen. Among total six patients without a T790M mutation, four received cytotoxic chemotherapy and two gefitinib beyond progression. Finally, medical oncologists and patients in another hospital had little opportunity to obtain information about the compassionate use program on osimertinib. To aid similar efforts, we have developed an online inquiry system for investigational trials on the web. This time, AstraZeneca conducted a compassionate use program on osimertinib under special or specified medical care coverage. Some pharmaceutical companies have been the major proponents in their own compassionate use programs, such as on gefitinib for NSCLC, crizotinib for ALK-positive NSCLC, and nivolumab for malignant melanoma. On the other hand, the Japanese Ministry of Health, Labour and Welfare established the extended investigational trial system (Japanese compassionate use program, cohort type) from January 2016, in which applicants are not only pharmaceutical companies, but also investigators and patients (23) . Thorough discussion with pharmaceutical companies about matters such as patient requests, safety, operation systems, and budget may enable cohort-type extended investigational trials to continue until the drug approval and reimbursement pricing stages. Recently, three extended investigational trials have been initiated in Japan:
(a) crizotinib for NSCLC harboring ROS1 alterations from 11 July 2016; (b) atezolizumab for urothelial cancer from 6 October 2016; and (c) nivolumab for head and neck squamous cell cancer from 6 October 2016.
Conclusion
In a compassionate use program, osimertinib demonstrated sufficient efficacy even in patients with heavily pretreated NSCLC harboring the T790M EGFR mutation. In particular, 33% of patients pretreated with another third-generation EGFR TKI responded to osimertinib. Special or specified medical care coverage, such as compassionate use programs or extended investigational trials, are important means of providing new anticancer agents until the drug approval and reimbursement pricing stages.
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